Harnessing CD8+CD28− Regulatory T Cells as a Tool to Treat Autoimmune Disease
T regulatory cell therapy presents a novel therapeutic strategy for patients with autoimmune
diseases or who are undergoing transplantation. At present, the CD4+ Treg population has …
diseases or who are undergoing transplantation. At present, the CD4+ Treg population has …
Assessing SARS-CoV-2-specific T-cell reactivity in late convalescents and vaccinees: Comparison and combination of QuantiFERON and activation-induced marker …
A Gatti, G Zizzo, M De Paschale, A Tamburello… - Plos one, 2023 - journals.plos.org
Objectives Monitoring of SARS-CoV-2 spread and vaccination strategies have relied on
antibody (Ab) status as a correlate of protection. We used QuantiFERON™(QFN) and …
antibody (Ab) status as a correlate of protection. We used QuantiFERON™(QFN) and …
Senescent CD4+CD28null cells are increased in chronic hyperuricemia, show aberrant effector phenotypes, and are reversed after allopurinol therapy: a proof-of …
LM Amezcua-Guerra, F Espinosa-Bautista… - Clinical …, 2023 - Springer
To characterize CD4+ CD28null cells in chronic hyperuricemia and investigate whether
allopurinol could restore CD28 expression and the balance of T helper phenotypes …
allopurinol could restore CD28 expression and the balance of T helper phenotypes …
[PDF][PDF] Harnessing CD8+CD28-Regulatory T Cells as a Tool to Treat Autoimmune Disease. Cells 2021, 10, 2973
T regulatory cell therapy presents a novel therapeutic strategy for patients with autoimmune
diseases or who are undergoing transplantation. At present, the CD4+ Treg population has …
diseases or who are undergoing transplantation. At present, the CD4+ Treg population has …
[引用][C] Имунорегулаторно действие на мезенхимни стволови клетки върху Т-лимфоцити на пациенти с ревматоиден артрит
ГХ Василев - 2021 - Медицински университет-София …